Biju et al. tested the use of genetically modified monocytes/macrophages to deliver GDNF as a therapy against Parkinson's disease in animal models, demonstrating the role of macrophages as a powerful tool for delivery and expression of therapeutic transgenes at the site(s) of neurodegeneration [56]. This evidence concerns the gene GDNF and Parkinson disease.